Tradestie Institutional Equity Comparison Engine

ENTA vs LBRX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

LBRX Overall Edge

LBRX Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to LB Pharmaceuticals Inc Common Stock (LBRX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while ENTA counters with relative strength in Valuation. Fundamentally, ENTA trades at 44.0x Forward P/E with -90.0% operating margin (-21.6% YoY revenue) versus LBRX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ENTA sits in BREAKDOWN (11th %ile IV; Dealer Gamma Walls on Pro) against LBRX sits in CONSOLIDATION (12th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ENTA
ENTA 44.0x vs LBRX N/M Fwd P/E
Growth & Margin Winner LBRX
Op Margin -90.0% vs 0.0% ยท YoY -21.6% vs +0.0%
Momentum & Technical Winner LBRX
1Y -7.9% vs +188.9% ยท 52W Pos 10% vs 80%
Options & Structure Winner LBRX
BREAKDOWN (11th %ile IV) vs CONSOLIDATION (12th %ile IV)
ENTA NASDAQ
Enanta Pharmaceuticals, Inc
Pharmaceutical Preparations
$10.79
-1.82% 1D
Market Cap $326.2M
1M Return -2.79%
1Y Return -7.94%
Forward P/E 44.0x
Unified AI Score
46.2 / 100 HOLD
Tech 53.0 Fund 54.0 Flow 67.0 Mom 50.0
LBRX NASDAQ
LB Pharmaceuticals Inc Common Stock
Pharmaceutical Preparations
$43.04
+0.07% 1D
Market Cap $1.4B
1M Return +17.15%
1Y Return +188.86%
Forward P/E N/M
Unified AI Score
35.5 / 100 SELL
Tech 8.0 Fund 32.0 Flow 54.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ENTA -7.94% LBRX +188.86% Spread: +196.8 pp (LBRX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ENTA TTM Op. Margin: -90.0% LBRX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ENTA vs LBRX. Trailing 12-month operating profitability (ENTA -90.0% vs LBRX 0.0%) and valuation multiples (ENTA 44.0x vs LBRX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ENTA (4) vs LBRX (6)
Institutional Metric ENTA LBRX Criterion Row Winner
Market Capitalization Scale $326.2M $1.4B Larger Scale LBRX
Trailing P/E Ratio Valuation 44.0x N/M Lower Multiple ENTA
Forward P/E Ratio Valuation 44.0x N/M Lower Multiple ENTA
Revenue Growth (YoY) Growth -21.6% +0.0% Higher Growth LBRX
Operating Margin (TTM) Profitability -90.0% 0.0% Higher Margin LBRX
Net Profit Margin Profitability -96.9% 0.0% Higher Margin LBRX
Return on Equity (ROE) Capital Efficiency -70.1% -38.8% Higher ROE LBRX
52-Week Range Position Momentum 10% ($10โ€“$17) 80% ($14โ€“$50) Stronger Trend LBRX
Beta / 30D Volatility Risk Regime 0.89ฮฒ ยท 58% Vol 1.04ฮฒ ยท 62% Vol Lower Realized Risk ENTA
Unified Institutional Score Composite Signal 46.2 / 100 (HOLD) 35.5 / 100 (SELL) Higher Composite ENTA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ENTA vs LBRX Buy Guide
ENTA BREAKDOWN
95d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 11th %ile
IV Regime Compressed (<25th %ile)
Live ENTA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
LBRX CONSOLIDATION
62d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 12th %ile
IV Regime Compressed (<25th %ile)
Live LBRX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ENTA nor LBRX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.